Periostat

Rocky Mountain Spotted Fever, Acinetobacter Infections, Ureaplasma Infections + 61 more

Treatment

93 FDA approvals

20 Active Studies for Periostat

What is Periostat

Doxycycline

The Generic name of this drug

Treatment Summary

Doxycycline is an antibiotic used to treat a wide range of bacterial infections. It is a synthetically derived version of the tetracycline family of antibiotics, with fewer side effects than the first-generation tetracyclines. Its effectiveness against specific bacteria can be determined through antibiotic susceptibility testing.

Vibramycin Hyclate

is the brand name

image of different drug pills on a surface

Periostat Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Vibramycin Hyclate

Doxycycline

1967

728

Approved as Treatment by the FDA

Doxycycline, otherwise known as Vibramycin Hyclate, is approved by the FDA for 93 uses such as Skin Infections and Secondary Syphilis .

Skin Infections

Secondary Syphilis

Listeria infection

Brucellosis

Used to treat Brucellosis in combination with Streptomycin

Staphylococcus (S.) Aureus Infection

Chlamydia Infections

Bacterial Infection caused by Enterobacter aerogenes

Calymmatobacterium granulomatis

Ureaplasma urethritis

Communicable Diseases

Klebsiella Infections

Typhus infections

Haemophilus Influenzae Infections

Bacteriological Techniques

Genus Chlamydia

Campylobacter Infections

Inclusion conjunctivitis

Chlamydia Infections

Urethritis

Typhus, Endemic Flea-Borne

Communicable Diseases

Dysentery, Bacillary

Gonorrhea

Bartonella Infections

Acne Vulgaris

Q Fever

Acinetobacter Infections

Ureaplasma Infections

Communicable Diseases

Uterine Cervicitis

Rocky Mountain Spotted Fever

Malaria

Relapsing Fever

Amebic colitis

Plague

Lymphogranuloma Venereum

Chlamydia trachomatis

Upper Respiratory Tract Infection

Tularemia

Relapsing fever caused by Borrelia recurrentis

Plasmodium Infections

Primary Syphilis

Anal chlamydia infection

Streptococcus Pneumoniae Infections

Yaws

Clostridium difficile Infection

Recurrent Upper and Lower Respiratory Tract Infections (RTIs)

Chlamydia trachomatis

Intestinal Amebiasis

Actinomycosis

Rickettsialpox

Necrotizing ulcerative gingivostomatitis

Cholera (Disorder)

Chlamydial cervicitis

Urinary Tract Infections

Mycoplasma Pneumoniae

Campylobacter Infection

Chancroid

Trachoma

Tick-borne fever

Chlamydial Urethritis

Neisseria Gonorrhoeae Infection

Severe Acne

Epididymo-orchitis gonococcal

Fever

Cat-Scratch Disease

Bartonella bacilliformis infections

Shigella Infection

inhaled anthrax caused by Bacillus anthracis

Pneumococcal Infections

Clostridium Infections

Common Cold

Brucellosis

Used to treat Brucellosis in combination with Streptomycin

Trachoma

Plague

Urethritis

Acinetobacter Infections

Yersinia pestis

Psittacosis

Chlamydia psitacci infection

Ureaplasma Infections

Infection Due to Escherichia Coli

Trachoma inclusion conjunctivitis

Listeriosis

Yaws

Relapsing Fever

Vibrio Cholerae Infection

Disease

Haemophilus ducreyi infection

Tularemia

prophylaxis of Malaria

Respiratory Tract Infections

Granuloma Inguinale

Effectiveness

How Periostat Affects Patients

Doxycycline and other tetracyclines stop bacteria from growing or keep them in a stationary state. They work against both gram-positive and gram-negative bacteria, and these bacteria are often resistant to tetracyclines. Doxycycline is a lipophilic drug, which means it can penetrate cells and has a wide range of effects, such as being antibacterial, antiparasitic, and anti-inflammatory. It has been used to treat skin conditions such as bullous dermatoses and rosacea.

How Periostat works in the body

Doxycycline stops bacteria from making necessary proteins that allow them to survive and function. It does this by blocking the binding of amino acids to ribosomes, which are responsible for making proteins. Doxycycline also blocks inflammation by preventing calcium-dependent cells from forming and stopping lymphocytes from growing. It also stops an enzyme that produces a molecule that causes inflammation.

When to interrupt dosage

The prescribed dose of Periostat is reliant upon the diagnosed condition, such as Urethritis, Chlamydia trachomatis and Respiratory Tract Infections. The measure of dosage differs, in accordance with the method of delivery (e.g. Capsule or Syrup - Oral) featured in the table underneath.

Condition

Dosage

Administration

Psittacosis

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Klebsiella Infections

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Actinomycosis

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Inclusion conjunctivitis

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Mycoplasma Pneumoniae

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Chlamydia trachomatis

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Haemophilus Influenzae Infections

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Primary Syphilis

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Haemophilus ducreyi infection

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Bartonella Infections

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Genus Chlamydia

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Acne Vulgaris

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Bacterial Infection caused by Enterobacter aerogenes

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Staphylococcus (S.) Aureus Infection

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Typhus, Endemic Flea-Borne

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Epididymo-orchitis gonococcal

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

inhaled anthrax caused by Bacillus anthracis

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Relapsing Fever

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Rocky Mountain Spotted Fever

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Yaws

10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg

, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension, For suspension - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder - Intravenous, Powder, Gel - Oral, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution - Intravenous, Injection, powder, for solution

Warnings

Periostat has three contraindications and should not be ingested when any of the conditions mentioned in the table below are present.

Periostat Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Doxycycline may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Doxycycline may interact with Pulse Frequency

There are 20 known major drug interactions with Periostat.

Common Periostat Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Doxycycline.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Doxycycline.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Doxycycline.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Doxycycline.

Amdinocillin

Major

The therapeutic efficacy of Amdinocillin can be decreased when used in combination with Doxycycline.

Periostat Toxicity & Overdose Risk

The toxic dose of doxycycline in rats is 2000mg/kg, 1870mg/kg in mice, and 500mg/kg in dogs. If an overdose happens, doxycycline should be stopped and supportive medical care should be given. Dialysis will not reduce the amount of the drug in the body and is not recommended for overdoses.

image of a doctor in a lab doing drug, clinical research

Periostat Novel Uses: Which Conditions Have a Clinical Trial Featuring Periostat?

34 ongoing studies are examining the potential of Periostat to combat Haemophilus Influenzae Infections, Respiratory Tract Infections and Amebic Colitis.

Condition

Clinical Trials

Trial Phases

Epididymo-orchitis gonococcal

0 Actively Recruiting

Lymphogranuloma Venereum

0 Actively Recruiting

Gonorrhea

0 Actively Recruiting

Plague

0 Actively Recruiting

Typhus, Endemic Flea-Borne

0 Actively Recruiting

Chlamydia Infections

7 Actively Recruiting

Not Applicable, Phase 4

inhaled anthrax caused by Bacillus anthracis

0 Actively Recruiting

Calymmatobacterium granulomatis

0 Actively Recruiting

Plague

0 Actively Recruiting

Haemophilus Influenzae Infections

0 Actively Recruiting

Urethritis

1 Actively Recruiting

Phase 2

Urinary Tract Infections

15 Actively Recruiting

Not Applicable, Phase 4, Early Phase 1, Phase 3

Pneumococcal Infections

0 Actively Recruiting

Clostridium difficile Infection

1 Actively Recruiting

Phase 2

Communicable Diseases

0 Actively Recruiting

Chlamydia trachomatis

0 Actively Recruiting

Chancroid

0 Actively Recruiting

Klebsiella Infections

0 Actively Recruiting

Rosacea

3 Actively Recruiting

Early Phase 1, Phase 2, Not Applicable

Rocky Mountain Spotted Fever

0 Actively Recruiting

Periostat Reviews: What are patients saying about Periostat?

5

Patient Review

2/8/2010

Periostat for Inflammation of the Gums and Mouth

I am a smoker with moderate to advanced periodontal disease. My periodontist performed scaling and root planning with localized surgical treatment. After several years in maintenance my condition began to breakdown. I began using periostat and slowly over the next nine months the periodontist noted a decrease in my bleeding and inflammation as well as my pocket depths. This medication has worked from inside my body to help control the inflammation response to my periodontal infection.

2.3

Patient Review

3/10/2010

Periostat for Inflammation of the Gums and Mouth

Since having a hysterectomy (not related to periostat), I've been having some serious digestive issues. Bloating, gas, indigestion; the works. I'm currently taking glutamine and probiotics, but I'm not sure if it's the medicine or not. I was on it for years before this happened, and the package did have warnings about long term use.

1

Patient Review

10/24/2008

Periostat for Additional Medication for Inflammation Around the Teeth

After having some dental work done, my dentist prescribed this medication. However, I had to stop taking it because it resulted in blood in my stool. I also had to stop taking other medications (simvastatin, baby aspirin and Chantix) until the condition clears up.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about periostat

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long should you use Periostat?

"PERIOSTAT is meant to be used for treatment periods of 3 months. It shouldn't be used for more than 3 consecutive three-month periods. There's no need to change the dosage for elderly patients."

Answered by AI

Is Periostat the same as doxycycline?

"Periostat is a drug used to help reduce pocket depth and promote attachment level gain in patients with adult periodontitis. The dosage of Periostat is different from that of doxycycline, which is used to treat infections."

Answered by AI

What is Periostat used for?

"Periostat is used to treat periodontitis, a condition that affects the gums and can cause teeth to become loose or fall out. The standard treatment for periodontitis is scaling and root planing, which is done by a dentist or dental hygienist."

Answered by AI

What is Periostat periodontics?

"Periostat is an orally administered tablet that contains a novel formulation of 23.08mg doxycycline hyclate. It is designed to be taken twice a day as an adjunct to scaling and root planing (SRP), and has been shown to increase clinical attachment level gain and reduce probing depths in patients with chronic periodontitis."

Answered by AI

Clinical Trials for Periostat

Image of Seattle Children's Hospital in Seattle, United States.

Follow-Up Strategies for Children With Medical Complexity

1 - 16
All Sexes
Seattle, WA

Children with medical complexity often receive a recommendation to see an outpatient clinician soon after leaving the hospital. It is uncertain whether every child needs this routine visit or whether follow-up can be guided by the family's concerns and the child's recovery. AFTERCARE is a multicenter pilot randomized trial comparing these two follow-up recommendations for children hospitalized with an acute infection. Families will be assigned by chance to receive either a recommendation to arrange follow-up with their usual outpatient clinician within seven days or a recommendation to seek follow-up if the child is not improving as expected or new concerns arise. Families in both groups may seek medical care whenever needed. The study will assess recruitment, follow-up data collection, delivery of the recommendations and acceptability. Caregiver surveys and medical record review will also describe outpatient visits and hospital returns. This pilot will inform the design of a larger trial, and is not designed to establish that the strategies are equally safe or effective.

Waitlist Available
Has No Placebo

Seattle Children's Hospital

Nassr Nama, MD, MSc

Image of National Institutes of Health Clinical Center in Bethesda, United States.

Imaging Scans for Malaria

18 - 54
All Sexes
Bethesda, MD

Background: Malaria is a serious disease caused by parasites spread by mosquitoes. To better diagnose and treat malaria, researchers need to learn more about where the parasites go when they enter a person's body. They want to see if they can locate the malaria parasites in the body using imaging scans. Objective: To learn whether imaging scans can locate parasites in people with malaria. Eligibility: Healthy people aged 18 to 54 years. They must be enrolled in protocol IRB001970 or IRB002627 for controlled malaria infection. Design: Participants will be screened. They will have blood drawn and a physical exam, including an abdominal exam to check the size of their spleen. Participants for this study will have 2 or 3 positron emission tomography/computed tomography (PET/CT) scans: The first will be about 3 days before they are deliberately infected with malaria for a different study. The second will be about 13 days later, while they have the disease. The third scan is optional; it will be done about 3 and 1/2 weeks after the second scan. For each scan, participants will receive a radioactive tracer called fluorodeoxyglucose (FDG). FDG will be injected through a tube inserted into a vein. They will lie on a table that slides through a doughnut-shaped machine. PET/CT uses x-rays to create images of the inside of the body. All participants will have a follow-up visit about 3 and 1/2 weeks after the second scan. The blood draw and physical exam will be repeated. This visit may be combined with the third scan for those who choose it.

Waitlist Available
Has No Placebo

National Institutes of Health Clinical Center

Shanan R Immel, M.D.

Image of William S. Middleton Memorial Veterans Hospital, Madison, WI in Madison, United States.

Resistant Potato Starch for Gut MDRO Decolonization

18+
All Sexes
Madison, WI

Multidrug-resistant organisms (MDROs) cause serious infections that are difficult to treat, leading to increased morbidity and mortality, longer hospital stays, and increased healthcare costs. Many risk factors for MDRO infections are present in the Veteran population (such as older age, underlying medical conditions like diabetes, and stays in long-term healthcare settings). Some people can carry these organisms in their gut. Even without current symptoms, carrying these MDROs also increases risk of future infection. Effective, easy to use, and inexpensive interventions to reduce gut carriage of MDROs are needed to reduce risk of infection. Dietary fiber prebiotics have shown promise in improving the healthy gut microbiome, and the investigators have found that individuals with high fiber in their diets have reduced carriage of MDROs in the gut. The investigators propose a randomized controlled trial to test the effectiveness of a dietary fiber prebiotic intervention (resistant potato starch) in reducing gut MDRO carriage in Veterans with a history of MDRO carriage and/or infection. The investigators will also evaluate the effect on the gut microbiome as well as Veterans' experience with the fiber intervention.

Phase 2
Waitlist Available

William S. Middleton Memorial Veterans Hospital, Madison, WI

Nasia Safdar, MD PhD

Have you considered Periostat clinical trials?

We made a collection of clinical trials featuring Periostat, we think they might fit your search criteria.
Go to Trials
Image of Anishnawbe Health Toronto in Toronto, Canada.

Xpert® HIV-1 Qual XC for HIV Detection

Any Age
All Sexes
Toronto, Canada

The goal of this cross-sectional study is to learn if the GeneXpert system is a practical system for HIV and STBBI testing in community-based organizations and health clinics. The study involves a clinical trial to learn if the HIV-1 Qual XC test works to identify HIV in near-patient settings. The main questions it aims to answer are to create a near-patient testing model for testing and treating patients in a single visit, and to learn if the HIV-1 Qual XC test works to accurately detect HIV in patients. Patients who come to study sites to ask for HIV or STBBI testing will be given the option to participate in the study. Those who agree with provide samples for the tests of their choice and answer survey questions before and after their tests are completed. Those who participate in the clinical trial will have a blood sample sent to provincial labs to compare the results to the HIV -1 Qual XC test. Follow-up visits will be done at 1,3 and 6 months to see if patients completed treatment and/or remained connected to care.

Waitlist Available
Has No Placebo

Anishnawbe Health Toronto (+1 Sites)

Have you considered Periostat clinical trials?

We made a collection of clinical trials featuring Periostat, we think they might fit your search criteria.
Go to Trials
Image of Coastal Family Health Center in Biloxi, United States.

PEACHES 2.0 Strategies for HIV/AIDS

18+
All Sexes
Biloxi, MS

This project will test ways to reduce stigma in healthcare settings so that more providers offer, and more patients receive, important anal sex-related HIV services, including anorectal sexually transmitted infection (STI) testing, preventive medications, and cancer screening. By evaluating these stigma-reduction strategies in eight clinics in the Mississippi Delta, a region with high rates of HIV and STIs, the research team will learn whether and how these approaches work to improve access to care. The results will help guide healthcare systems in using the most effective methods to reduce stigma, making it easier for people to get prevention services and improving public health.

Waitlist Available
Has No Placebo

Coastal Family Health Center

Bryan Kutner, PhD, MPH

Image of University of North Carolina in Chapel Hill, United States.

BLTR vs B-RAP for Trichiasis

18+
All Sexes
Chapel Hill, NC

The primary objective of this randomized clinical trial is to determine whether repeat trichiasis surgery performed with Bevel-Rotate Advancement Procedure (B-RAP) improves surgical success compared to Bilamellar Tarsal Rotation (BLTR) among a group of 8-10 TT surgeons in Tanzania. The study aims to enroll 1,000 individuals with PTT. The primary outcome is repeat PTT within one year after surgery. Additionally, the study will assess eyelid contour abnormalities and how they change over a two-year period as well as patient reported outcomes. If this project is successful in improving surgical outcomes, it could change the approach to treating PTT globally. Individuals with trichiasis have a significantly reduced quality of life; correcting their trichiasis long-term has the potential to improve their quality of life and their family members' quality of life considerably.

Recruiting
Has No Placebo

University of North Carolina

Emily Gower, PhD

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 days - 17 years
All Sexes
Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4
Waitlist Available

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Have you considered Periostat clinical trials?

We made a collection of clinical trials featuring Periostat, we think they might fit your search criteria.
Go to Trials